The PE Ratio as of December 2024 (TTM) for Tarsus Pharmaceuticals, Inc. (TARS) is -14.41

According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -14.41. This represents a change of 68.48% compared to the average of -8.55 of the last 4 quarters.

Tarsus Pharmaceuticals, Inc. (TARS) Historical PE Ratio (quarterly & annually)

How has TARS PE Ratio performed in the past?

The mean historical PE Ratio of Tarsus Pharmaceuticals, Inc. over the last ten years is -37.97. The current -14.41 PE Ratio has changed 3.70% with respect to the historical average. Over the past ten years (40 quarters), TARS's PE Ratio was at its highest in in the June 2021 quarter at 23.47. The PE Ratio was at its lowest in in the September 2019 quarter at -82.36.

Tarsus Pharmaceuticals, Inc. (TARS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Tarsus Pharmaceuticals, Inc. (TARS) Average PE Ratio

How has TARS PE Ratio performed in the past?

The current PE Ratio of Tarsus Pharmaceuticals, Inc. (TARS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Tarsus Pharmaceuticals, Inc. (TARS) PE Ratio vs. Peers

How is TARS’s PE Ratio compared to its peers?

Tarsus Pharmaceuticals, Inc.’s PE Ratio is less than LianBio (-0.75), less than Aldeyra Therapeutics, Inc. (-6.32), less than Travere Therapeutics, Inc. (-3.79), greater than Eton Pharmaceuticals, Inc. (-59.82), less than Connect Biopharma Holdings Limited (7.21), less than Acumen Pharmaceuticals, Inc. (-1.32), less than Nuvation Bio Inc. (-1.45), less than Eledon Pharmaceuticals, Inc. (18.27), less than Opthea Limited (-1.15), less than Centessa Pharmaceuticals plc (-12.16), greater than Nuvalent, Inc. (-24.20), less than Genfit S.A. (122.03), less than Monte Rosa Therapeutics, Inc. (-4.84), less than Design Therapeutics, Inc. (-7.53), less than Werewolf Therapeutics, Inc. (-1.08), less than Ikena Oncology, Inc. (-1.24), less than Stoke Therapeutics, Inc. (-6.05), less than PepGen Inc. (-1.51), less than Tyra Biosciences, Inc. (-9.91), less than Entrada Therapeutics, Inc. (12.98), less than Pharvaris N.V. (-7.35), less than Rallybio Corporation (-0.57),

Build a custom stock screener for Tarsus Pharmaceuticals, Inc. (TARS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tarsus Pharmaceuticals, Inc. (TARS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.